Epigenetics Market

Epigenetics Market Analysis By Product (Epigenetic Kits, Epigenetic Reagents, Epigenetic Enzymes, Bioinformatics Tools, Epigenetics Instruments and Consumables) By Technology, By Application, and By Region – Global Market Insights 2022 to 2032

Analysis of Epigenetics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Epigenetics Market Outlook (2022-2032)

The global epigenetics market size in 2022 is valued at US$ 992.8 million and is expected to attain an estimated revenue total of US$ 2.79 billion by the end of the forecast period. Demand for epigenetics is predicted to increase at an impressive CAGR of 10.9% from 2022 to 2032.

The expansion of the epigenetic diagnostics market is projected to drive demand for products such as DNA-modifying enzymes, mass spectrometers, bisulfite conversion kits, sonicators, etc.

Report Attributes

Details

Epigenetics Market Size (2022)

US$ 992.8 Million

Predicted Market Value (2032F)

US$ 2.79 Billion

Projected Market Growth Rate (2022-2032)

10.9% CAGR

Europe Epigenetics Market Share (2022)

27.1%

Market Share of Top 3 Countries

33.2%

Key Companies Profiled

  • Thermo Fisher Scientific
  • PerkinElmer
  • Illumina
  • New England Biolabs
  • Merck Millipore
  • Abcam
  • Agilent
  • Zymo Research
  • Bio-Rad Laboratories
  • QIAGEN
  • Active Motif
  • Diagenode

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Epigenetics Revenue Analysis (2017-2021) Vs. Market Estimations (2022-2032)

Epigenetic biomarkers and diagnostics have played a crucial role in the detection and management of various diseases over the past few years and as focus on epigenetics bolsters it will fuel research activity in the field of epigenetics.

Protein-modifying enzymes and RNA-modifying enzymes are expected to witness a rise in demand as the application of epigenetics in oncology increases. The increasing prevalence of chronic diseases is expected to primarily drive the adoption of epigenetic products such as RNA sequencing kits, whole genomic amplification kits, and other next-generation sequencers.

Increasing investments in epigenetics research and supportive government initiatives to advance research in epigenetics to enhance healthcare infrastructure are also expected to favour epigenetics market growth through 2032.

However, the absence of skilled professionals to operate advanced epigenetic analysis tools and the high costs associated with the installation and maintenance of these tools are expected to restrain overall epigenetics market growth. The epigenetics market is projected to expand at an impressive CAGR of 10.9% through 2032.

Epigenetics market forecast by Fact.MR

What are the Main Trends in the Epigenetics Market?

“Market Rising on Back of Increasing Popularity of Epigenetic DNA Methylation”

Adoption of DNA methylation technology to study the human genome and novel therapy development is expected to propel epigenetics market potential over the forecast period. Start-ups, as well as established players, are raising funds and increasing their investments in advancing their DNA methylation research.

  • For instance, Base Genomics, an epigenetics firm, now known as Exact Sciences Innovation Ltd., raised around US$ 11 million in 2020 in a seed round to advance its DNA methylation technology research & development program.

“High Cost of Epigenetic Technology Could Dent Market Growth Potential”

The epigenetic instruments market is expected to be hampered by the high costs associated with the installation and maintenance of epigenetic instruments in research facilities. This factor hinders the adoption of epigenetics in developing economies where sending potential is limited and budget caps make it difficult to maintain the equipment.

Epigenetic instrument manufacturers are expected to invest in the development of low-cost instruments to attain maximum market penetration over the coming years.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

What Strategies Should Start-ups Deploy to Excel in Epigenetics?

“New Companies Can Target Mergers & Collaborations”

Epigenetics research incurs high costs to companies and is a very investment-intensive market to tap into. Start-ups looking to enter the epigenetics market should bolster their research and target the development of innovative solutions to build a sustainable business model.

Start-ups can band together to form partnerships and collaborations to advance their research and fast-track the development of their offerings. This enables thorough research of their offerings and also reduces the revenue spent on research. This multidisciplinary approach can also unlock new possibilities that could revolutionize the field of epigenetics.

  • Element Biosciences Inc., a start-up based in the United States, has focused on developing innovative genetic analysis tools for research and diagnostic purposes. In February 2022, it announced a partnership with Dovetail Genomics a firm focused on redefining genomic biology. The partnership will explore and demonstrate Dovetail’s ligation-based next-generation sequencing (NGS) library prep solutions on Element’s novel AVITI System.

Which Regional Markets Will Exhibit Promising Growth Opportunities?

“North America & Europe Influentially Driving Epigenetic Products Market Potential”

The North America epigenetics market is predicted to exhibit highly rewarding opportunities for epigenetics market players over the forecast period. The North America epigenetics market accounts for a significant market share of 24.7% in the global landscape and stands at a valuation of US$ 245 million in 2022.

High investments in research activities and rising support from governments to boost epigenetics research are prominent factors that are expected to drive demand for epigenetics in this region through 2032. Increasing geriatric population and rising healthcare expenditure are also expected to favour epigenetics market potential.

The epigenetics market in Europe currently stands at a revenue total of US$ 269 million and is expected to be primarily driven by the increasing incidence of cancer in this region.

High investments in research activities and rising demand for cancer treatment are prime factors propelling epigenetics market growth in this region. Germany, France, and Italy are expected to be notable markets in this region throughout the forecast period.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Competitive Landscape

Epigenetic providers are focusing on mergers, collaborations, acquisitions, and partnerships to expand their business scope and bolster their research and development activities to fast-track the launch of innovative epigenetic technologies.

  • In August 2021, Grail, a company focused on the early detection of various types of cancers, was acquired by Illumina Inc., a leading American biotechnology company. Grail is prepping its application for an FDA approval of its Galleri test and was enrolling patients for the trial to expand its dataset focusing on the genome associated with cancer-causing epigenetic factors.

Fact.MR, a market research and competitive intelligence provider, has profiled key companies such as Thermo Fisher Scientific, PerkinElmer, Illumina, New England Biolabs, Merck Millipore, Abcam, and Agilent, among others, in this latest epigenetics market survey.

Key Segments Covered in Epigenetics Industry Research

  • By Product :

    • Epigenetic Kits
    • Epigenetic Reagents
    • Epigenetic Enzymes
    • Bioinformatics Tools
    • Epigenetics Instruments and Consumables
    • Others
  • By Technology :

    • Epigenetics DNA Methylation
    • Histone Methylation
    • Histone Acetylation
    • MicroRNA modification
    • Chromatic structures
    • Others
  • By Application :

    • Immunology
    • Oncology
    • Cardiovascular Diseases
    • Metabolic Diseases
    • Non-Oncology
    • Others
  • By Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

- FAQs -

What is the current valuation of the epigenetics market?

The global epigenetics market accounts for a valuation of US$ 992.8 million.

What size will the epigenetics market reach by 2032?

The epigenetics market is slated to reach US$ 2.79 billion by 2032.

At what CAGR is the market predicted to expand?

Between 2022 and 2032, the epigenetics market is set to expand at 10.9% CAGR.

What is the China epigenetics market value?

At present, the China epigenetics market stands at US$ 110 million.

Epigenetics Market

Schedule a Call